<DOC>
	<DOCNO>NCT00270036</DOCNO>
	<brief_summary>The purpose study determine safety epoetin alfa determine effectiveness epoetin alfa reduce need blood transfusion major orthopedic surgery . Epoetin alfa genetically engineer protein stimulates red blood cell production .</brief_summary>
	<brief_title>A Study Determine Safety Epoetin Alfa Whether Epoetin Alfa Can Reduce Need Blood Transfusions Patients After Major Orthopedic Surgery .</brief_title>
	<detailed_description>Patients undergo major orthopedic surgery frequently require blood transfusion operation . Agents increase rate red blood cell production would reduce need blood transfusion . Epoetin alfa genetically engineer form natural hormone , erythropoietin , stimulates red blood cell production . This randomized , double-blind , placebo-controlled , parallel group , multicenter study . The study compare effectiveness epoetin alfa reduce need blood transfusion patient expect require least 2 unit blood follow major orthopedic surgery . Eligible patient randomly assign receive either epoetin alfa ( 100 300 U/kg , depend upon body weight ) match placebo , injection beneath skin start 10 day schedule surgery , day surgery ( surgery ) , 4 day surgery . Additionally , patient start take oral iron supplement least 10 day schedule surgery . Effectiveness determine number transfusion require follow surgery , change hematocrit ( iron-containing pigment red blood cell ) , hemoglobin ( oxygen-carrying component red blood cell ) , reticulocyte ( immature red blood cell ) level start study end study . Safety evaluation include incidence severity adverse event , change clinical laboratory test , vital sign , physical examination finding throughout study . The study hypothesis patient treat epoetin alfa require few blood transfusion surgery patient treat placebo . Epoetin alfa ( 300 U/kg 100 U/kg ) , match placebo , injection beneath skin begin 10 day schedule surgery end 4 day surgery .</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients schedule major orthopedic surgery expect require transfusion least 2 unit red blood cell unwilling unable participate transfusion program wherein patient 's blood donate surgery significantly abnormal blood urine test result hematocrit &lt; = 45 % Patients blood disease , significant heart blood vessel disease sign symptoms significant disease and/or dysfunction sign symptom significant ongoing blood loss seizure disorder , uncontrolled high blood pressure , infection cancer may make difficult respond study drug receive medication know suppress formation red blood cell within 1 month start study receive blood transfusion within 1 month start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Blood transfusion</keyword>
	<keyword>epoetin alfa</keyword>
	<keyword>epogen</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>orthopedic procedure</keyword>
	<keyword>orthopedic surgery</keyword>
</DOC>